DENTSPLY SIRONA Inc. $XRAY Shares Acquired by Great Hill Capital LLC

Great Hill Capital LLC lifted its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 39.4% during the first quarter, Holdings Channel.com reports. The fund owned 1,008,274 shares of the medical instruments supplier’s stock after acquiring an additional 284,989 shares during the period. DENTSPLY SIRONA accounts for approximately 0.8% of Great Hill Capital LLC’s holdings, making the stock its 11th biggest holding. Great Hill Capital LLC’s holdings in DENTSPLY SIRONA were worth $11,696,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Goldman Sachs Group Inc. raised its holdings in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after buying an additional 2,172,343 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of DENTSPLY SIRONA by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after buying an additional 41,579 shares during the period. Finally, Focus Partners Wealth grew its holdings in shares of DENTSPLY SIRONA by 59.1% during the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after buying an additional 9,355 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Analysts Set New Price Targets

XRAY has been the topic of several research reports. UBS Group cut their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Mizuho cut their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barclays reduced their price objective on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Thursday, June 4th. Finally, Citigroup assumed coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and a consensus price target of $13.55.

DENTSPLY SIRONA Trading Down 1.6%

NASDAQ XRAY opened at $12.13 on Tuesday. DENTSPLY SIRONA Inc. has a 1 year low of $9.40 and a 1 year high of $17.09. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The company has a market capitalization of $2.43 billion, a PE ratio of -3.87, a P/E/G ratio of 1.39 and a beta of 0.89. The company has a fifty day moving average of $10.58 and a 200 day moving average of $11.65.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The business’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts forecast that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Michael J. Barber acquired 15,175 shares of the stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the transaction, the director owned 55,943 shares in the company, valued at approximately $552,716.84. This trade represents a 37.22% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian T. Gladden acquired 9,985 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the purchase, the director directly owned 61,849 shares in the company, valued at approximately $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 35,160 shares of company stock valued at $351,179 over the last ninety days. Company insiders own 0.46% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.